Evidence map›Paper›PMID 35399568›Full record

ArticleTranslational lung cancer research2022

Clinicopathologic and molecular characteristics of

Li Yu, Lyudmila Bazhenova, Kathryn Gold, Lisa Tran, Van Hilburn, Peter Vu, Sandip Pravin Patel

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 3 pooled it
2.2field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. De Novo SCLC Transformation FromJTO clinical and research reports · 2023
    Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Li YuDepartment of Oncology, Shengjing Hospital of China Medical University, Shenyang, China.
Lyudmila BazhenovaMoores Cancer Center, University of California, San Diego, CA, USA.
Kathryn GoldMoores Cancer Center, University of California, San Diego, CA, USA.
Lisa TranMoores Cancer Center, University of California, San Diego, CA, USA.
Van HilburnMoores Cancer Center, University of California, San Diego, CA, USA.
Peter VuMoores Cancer Center, University of California, San Diego, CA, USA.
Sandip Pravin PatelMoores Cancer Center, University of California, San Diego, CA, USA.
University of California, San Diego · USChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Small cell lung cancer (SCLC) transformation is one of the mechanisms of drug resistance to tyrosine kinase inhibitors (TKIs) in advanced epidermal growth factor receptor ( Methods: We performed a retrospective review of 964 cases at the University of California, San Diego of patients with Results: Nine cases (9/964, 0.9%) were identified, all with stage IV adenocarcinoma (ADC) at diagnosis, 7 were poorly differentiated, and 7 had an Conclusions: In our series, most patients with small cell transformation had poorly differentiated adenocarcinomas at baseline.

Indexed as

EGFR mutationLung adenocarcinomasmall cell lung cancer (SCLC)transformationtyrosine kinase inhibitor (TKI)

Identifiers

PMID35399568
PMCPMC8988081
OpenAlexW4214570914

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.